Please login to the form below

Healthcare tech: the driving force behind value-based care?

In 2020, healthcare technology investment went into overdrive. We speak to Sunny Kumar, Partner at GSR Ventures, to find out how COVID‑19 has transformed the industry and whether healthcare technology can bring us one step closer to a value-based model of care.

The COVID-19 pandemic has brought about the most unexpected and unprecedented challenges, stretching our finite healthcare resources to an extent where they have reached a breaking point. The pandemic forced healthcare systems and providers to become more agile, and the industry has adopted technologies at a rate like never before.

The numbers speak for themselves. During  the last 10 years, investments in the health-tech sector trended between $2 to $5 billion. In 2020 alone, this number rose to more than $14 billion.So how has this rapid adoption of technology transformed the way care is delivered?

Fishawack Health talks to physician and AI informatics expert turned venture capitalist Sunny Kumar to learn how the healthcare technology landscape has changed because of COVID-19. He reveals how innovative technology drives us closer to value-based care and the trends he thinks are worth the hype.

What’s your role at GSR ventures?

SK: As a partner at GSR Ventures, I oversee healthcare technology investments. We structure our work in a full-stack manner. So, I am involved in everything from developing our investment thesis to finding visionary entrepreneurs to partner with and determining which companies are most likely to create transformative impact in a sector. Once we partner with a company, I support our founders as they scale up and, at the appropriate time, help elevate those companies to the next level.

Do you think the pandemic has been a catalyst for changes in the way care is delivered?

SK: Healthcare is becoming more consumerized. Patients are looking for options designed around them, as opposed to the more traditional one‑size‑fits‑all healthcare system. A meaningful set of patients prefer to get their care delivered through technology, for example, via text message. They want to be able to get everything they need at the click of a button—that really didn’t exist before in a scalable manner.

The historical constraints of having to receive your healthcare in a physical clinic are also becoming less limiting. We’ve partnered with several companies in this space, including Medable, which helps transform traditional clinical trials through technology.

Instead of requiring patients to visit big academic medical centers many times throughout the clinical trial, Medable moves the trial out of the hospital and into the patient’s home by using technologies to collect or report information and enable remote patient-provider interactions. Pharmaceutical companies and contract research organizations (CRO) are now adopting this platform technology at a lightning pace.

This rapid transformation is happening on the patient side as well. For example, we have partnered with Alpha Medical, a company that delivers asynchronous telemedicine focused on women’s health. They are using technology to ensure that women can access convenient and personalized care, no matter how far away they are from a medical facility. Imagine the impact of being able to receive the best care anywhere in the country at a fraction of the cost… That’s what Alpha Medical is delivering today.


29th June 2021



Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

No. 3 Booths Park
Booths Hall
Chelford Road
WA16 8GS
United Kingdom

Latest content on this profile

Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
Omnichannel scientific engagement and the use of archetypes to drive personalization
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.
Fishawack Health
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Fishawack Health